D-erythro-Sphingosine-d7(Synonyms: Erythrosphingosine-d7; erythro-C18-Sphingosine-d7; trans-4-Sphingenine-d7)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
D-erythro-Sphingosine-d7 (Synonyms: Erythrosphingosine-d7; erythro-C18-Sphingosine-d7; trans-4-Sphingenine-d7)

D-erythro-Sphingosine-d7 (Erythrosphingosine-d7) 是 D-erythro-Sphingosine 的氘代物。D-erythro-Sphingosine (Erythrosphingosine) 是一种非常有效的 p32 激酶活化剂，EC50 为 8 μM。D-erythro-Sphingosine 抑制蛋白激酶 C (PKC)。D-erythro-Sphingosine (Erythrosphi

D-erythro-Sphingosine-d7(Synonyms: Erythrosphingosine-d7; erythro-C18-Sphingosine-d7; trans-4-Sphingenine-d7)

D-erythro-Sphingosine-d7 Chemical Structure

CAS No. : 1246304-34-6

规格 是否有货
500 μg 询价

* Please select Quantity before adding items.

生物活性

D-erythro-Sphingosine-d7 (Erythrosphingosine-d7) is the deuterium labeled D-erythro-Sphingosine. D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator[1][2][3][4].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

306.54

Formula

C18H30D7NO2
CAS 号

1246304-34-6
中文名称

D-赤式鞘氨醇 d7
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Pushkareva MYu, et al. Regulation of sphingosine-activated protein kinases: selectivity of activation by sphingoid basesand inhibition by non-esterified fatty acids. Biochem J. 1993 Sep 15;294 ( Pt 3):699-703.

    [3]. Khan WA, et al. Protein kinase C and platelet inhibition by D-erythro-Sphingosine: comparison with N,N-dimethylsphingosine and commercial preparation. Biochem Biophys Res Commun. 1990 Oct 30;172(2):683-91.

    [4]. Pham VT, et al. A concise synthesis of a promising protein kinase C inhibitor: D-erythro-Sphingosine. Arch Pharm Res. 2007 Jan;30(1):22-7.

    [5]. Cheng P, et al. Protein phosphatase 2A (PP2A) activation promotes axonal growth and recovery in the CNS. J Neurol Sci. 2015 Dec 15;359(1-2):48-56.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务